Critical Survey: Adicet Bio (NASDAQ:ACET) versus Virax Biolabs Group (NASDAQ:VRAX)

Virax Biolabs Group (NASDAQ:VRAX) and Adicet Bio (NASDAQ:ACET) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional & Insider Ownership

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 83.9% of Adicet Bio shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 4.6% of Adicet Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Virax Biolabs Group and Adicet Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10,000.00	89.49	-$6.06 million	N/A	N/A
Adicet Bio	N/A	N/A	-$117.12 million	($20.16)	-0.34

Virax Biolabs Group has higher revenue and earnings than Adicet Bio.

Volatility & Risk

Virax Biolabs Group has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Adicet Bio has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.

Profitability

This table compares Virax Biolabs Group and Adicet Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Adicet Bio	N/A	-77.90%	-64.35%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Virax Biolabs Group and Adicet Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1	1	1	0	2.00
Adicet Bio	1	1	4	1	2.71

Virax Biolabs Group currently has a consensus price target of $1.00, suggesting a potential upside of 384.97%. Adicet Bio has a consensus price target of $69.00, suggesting a potential upside of 895.67%. Given Adicet Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Adicet Bio is more favorable than Virax Biolabs Group.

Summary

Virax Biolabs Group beats Adicet Bio on 6 of the 11 factors compared between the two stocks.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

About Adicet Bio

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.